Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation

European Journal of Neurology

Volumn 19, Issue 1, 2012, Pages 76-83

  Elia, A E ^a   Dollenz, C ^a   Soliveri, P ^a   Albanese, A ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Apomorphine; Deep brain stimulation; Dyskinesias; Levodopa; Motor fluctuations; Parkinson's disease; Subthalamic nucleus

Indexed keywords

APOMORPHINE; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; MALE; MONOTHERAPY; MORNING DOSAGE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DEEP BRAIN STIMULATION; DYSKINESIAS; FEMALE; HUMANS; HYPODERMOCLYSIS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE;

EID: 84155165595     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03437.x     Document Type: Article

References (37)

1. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230.
2. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9: 163-168.
3. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235-1241.
4. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
5. Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8years after subthalamic implants. Brain 2010; 133: 2664-2676.
6. Oertel W, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson's disease. In: Gilhus NE, Barnes M, Brainin M eds. European Handbook of Neurological Management, 2nd edn. Oxford: Wiley-Blackwell, 2011: 237-267.
7. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
8. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63-73.
9. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581-591.
10. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
11. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23: 1130-1136.
12. Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol 2010; 257(Suppl. 2): S298-S304.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
14. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584.
15. Moro E, Esselink RJ, Xie J, Hommel M, Benabid AL, Pollak P. The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology 2002; 59: 706-713.
16. Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord 2009; 24: 555-561.
17. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M eds. Recent Developments in Parkinson's disease, 2 edn. Florham Park: Macmillan Healthcare Information, 1987: 153-163.
18. National Institute of Mental Health. AIMS, Abnormal Involuntary Movement Scale. In: Guy W ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976: 534-537.
19. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008; 23(Suppl. 3): S580-S584.
20. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996; 46: 1430-1436.
21. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996; 46: 1051-1054.
22. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006; 45: 109-136.
23. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007; 2: 234-243.
24. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006; 77: 450-453.
25. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011; 258: 579-585.
26. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009; 119: 345-348.
27. Stocchi F, Berardelli A, Vacca L, et al. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin Neuropharmacol 2003; 26: 151-155.
28. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151-157.
29. Caparros-Lefebvre D, Blond S, Feltin MP, Pollak P, Benabid AL. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. J Neurol Neurosurg Psychiatry 1999; 67: 308-314.
30. The Deep-brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345: 956-963.
31. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-1703.
32. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149.
33. Del Sorbo F, Albanese A. Levodopa-induced dyskinesias and their management. J Neurol 2008; 255(Suppl. 4): 32-41.
34. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993; 43: 1545-1550.
35. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21(Suppl. 14): S290-S304.
36. Ostergaard K, Sunde N. Evolution of Parkinson's disease during 4years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006; 21: 624-631.
37. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 2008; 275: 1392-1399.